PE20081705A1 - Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene - Google Patents
Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contieneInfo
- Publication number
- PE20081705A1 PE20081705A1 PE2008000198A PE2008000198A PE20081705A1 PE 20081705 A1 PE20081705 A1 PE 20081705A1 PE 2008000198 A PE2008000198 A PE 2008000198A PE 2008000198 A PE2008000198 A PE 2008000198A PE 20081705 A1 PE20081705 A1 PE 20081705A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- macrolide compound
- solid form
- preparation
- solid
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO MACROLIDO DE FORMA SOLIDA DENOMINADO (8E,12E,14E)-7-{(4-CICLOHEPTILPIPERAZIN-1-IL)CARBONIL}OXI-3,6,16,21-TETRAHIDROXI-6,10,12,16,20-PENTAMETIL-18,19-EPOXITRICOSA-8,12,14-TRIEN-11-OLIDO, DE FORMULA (I), DONDE LA FORMA SOLIDA CRISTALINA PRESENTA UN PATRON DE DIFRACCION DE RAYOS X EN POLVO, CON PICOS EN ANGULOS DE 2? ± 0.2, DE 8.8, 15.8 Y 17.5. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SUPRIMEN EL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) Y ES UTIL EN EL TRATAMIENTO DE TUMORES SOLIDOS Y SIMILARES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007017491 | 2007-01-29 | ||
US88825707P | 2007-02-05 | 2007-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081705A1 true PE20081705A1 (es) | 2008-12-22 |
Family
ID=39674155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000198A PE20081705A1 (es) | 2007-01-29 | 2008-01-28 | Compuesto macrolido en forma solida, proceso para su preparacion y composicion farmaceutica que lo contiene |
Country Status (17)
Country | Link |
---|---|
US (1) | US7790887B2 (es) |
EP (1) | EP2116542A4 (es) |
JP (1) | JPWO2008093853A1 (es) |
KR (1) | KR20090104002A (es) |
CN (1) | CN101616912A (es) |
AR (1) | AR065045A1 (es) |
AU (1) | AU2008211950A1 (es) |
BR (1) | BRPI0805837A2 (es) |
CA (1) | CA2673734A1 (es) |
CL (1) | CL2008000231A1 (es) |
IL (1) | IL200103A0 (es) |
MX (1) | MX2009008068A (es) |
NZ (1) | NZ575828A (es) |
PE (1) | PE20081705A1 (es) |
RU (1) | RU2009132476A (es) |
WO (1) | WO2008093853A1 (es) |
ZA (1) | ZA200904530B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI334866B (en) * | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
BRPI0805837A2 (pt) | 2007-01-29 | 2011-08-30 | Eisai R&D Man Co Ltd | forma sólida de um composto, método para preparação dos cristais, composição farmacêutica, método de tratamento de cáncer, e uso do composto sólido |
EP2168961A1 (en) * | 2007-07-06 | 2010-03-31 | Eisai R&D Management Co., Ltd. | Process for producing macrolide compound and intermediate therefor |
IL303335B1 (en) | 2018-04-09 | 2024-09-01 | Eisai R&D Man Co Ltd | Palladianolide compounds and their use |
TWI834655B (zh) | 2018-04-12 | 2024-03-11 | 日商衛材R&D企管股份有限公司 | 特定芳基普拉二烯內酯化合物及其使用方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL27183A (en) | 1966-02-01 | 1970-07-19 | Upjohn Co | Parenteral composition comprising freeze dried mannitol |
JPS6054933B2 (ja) | 1978-01-27 | 1985-12-03 | 小野薬品工業株式会社 | プロスタグランジン及びプロスタグランジン類似化合物製剤の安定化法 |
JPH04352783A (ja) | 1991-05-27 | 1992-12-07 | Taisho Pharmaceut Co Ltd | 12員環マクロライド系化合物 |
PL316995A1 (en) | 1994-04-25 | 1997-03-03 | Kyowa Hakko Kogyo Kk | Method of stabilising the dx-52-1 compound and freeze dried compositions thereof |
EP1192147A1 (en) | 1999-06-03 | 2002-04-03 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Mycolactone and related compounds, compositions and methods of use |
US6391903B1 (en) | 1999-09-09 | 2002-05-21 | Sankyo Company, Limited | Triazole derivatives having antifungal activity |
JP3240129B1 (ja) * | 1999-09-09 | 2001-12-17 | 三共株式会社 | トリアゾール抗真菌剤 |
JP4953501B2 (ja) * | 1999-09-30 | 2012-06-13 | 大塚化学株式会社 | 3−セフェム誘導体結晶の製造方法 |
AU2001278155A1 (en) | 2000-08-03 | 2002-02-18 | Kosan Biosciences, Inc. | Fermentation and purification of mycolactones |
TWI311558B (en) | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
TWI233361B (en) | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
JP2004269488A (ja) | 2002-06-06 | 2004-09-30 | Hayashibara Biochem Lab Inc | 結晶α−D−グルコシルα−D−ガラクトシドとこれを含有する糖質及びこれらの製造方法並びに用途 |
BR0313039A (pt) | 2002-07-31 | 2005-08-09 | Mercian Corp | Composto, medicamento, composição farmacêutica, método para prevenir ou tratar uma doença contra a qual um controle da expressão do gene é eficaz, método para prevenir ou tratar uma doença contra a qual a supressão da produção de vegf é eficaz, método para prevenir ou tratar uma doença contra a qual uma inibição da angiogênese é eficaz, uso do composto, método para produzir um composto 9-desoxi 1107, linhagem streptomyces sp. a-1543 (ferm bp-8442), método de produzir um composto 6- desoxi, e linhagem a-1544 (ferm bp-8446) ou linhagem a-1545 (ferm bp-8447) |
US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
CA2507641A1 (en) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Method of producing macrolide compound |
KR100732100B1 (ko) | 2003-05-07 | 2007-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 메틸코발라민 함유 동결 건조 제제 및 그의 제조 방법 |
CA2553573A1 (en) | 2004-01-29 | 2005-08-11 | Eisai R & D Management Co., Ltd. | Method for stabilizing macrolide compound |
US20080280288A1 (en) * | 2004-02-06 | 2008-11-13 | Toshimitsu Uenaka | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug |
JP2007269628A (ja) * | 2004-05-28 | 2007-10-18 | Takeda Chem Ind Ltd | 医薬化合物の結晶 |
JP2007519758A (ja) * | 2004-12-01 | 2007-07-19 | テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ | 結晶マクロライドの生成方法 |
KR100598119B1 (ko) | 2005-01-17 | 2006-07-10 | 삼성전자주식회사 | 디스플레이장치 및 그 제어방법 |
CA2607639A1 (en) | 2005-05-11 | 2006-11-16 | Eisai R & D Management Co., Ltd. | Crystal of indole derivative having piperidine ring and process for production thereof |
EP1935893A4 (en) | 2005-10-13 | 2009-07-22 | Eisai R&D Man Co Ltd | TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D |
CA2659562A1 (en) | 2006-08-14 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Stable lyophilized preparation |
BRPI0805837A2 (pt) | 2007-01-29 | 2011-08-30 | Eisai R&D Man Co Ltd | forma sólida de um composto, método para preparação dos cristais, composição farmacêutica, método de tratamento de cáncer, e uso do composto sólido |
-
2008
- 2008-01-28 BR BRPI0805837-7A patent/BRPI0805837A2/pt not_active IP Right Cessation
- 2008-01-28 JP JP2008556207A patent/JPWO2008093853A1/ja not_active Withdrawn
- 2008-01-28 AR ARP080100323A patent/AR065045A1/es unknown
- 2008-01-28 AU AU2008211950A patent/AU2008211950A1/en not_active Withdrawn
- 2008-01-28 PE PE2008000198A patent/PE20081705A1/es not_active Application Discontinuation
- 2008-01-28 NZ NZ575828A patent/NZ575828A/en unknown
- 2008-01-28 MX MX2009008068A patent/MX2009008068A/es not_active Application Discontinuation
- 2008-01-28 RU RU2009132476/04A patent/RU2009132476A/ru not_active Application Discontinuation
- 2008-01-28 KR KR1020097012762A patent/KR20090104002A/ko not_active Application Discontinuation
- 2008-01-28 US US12/021,184 patent/US7790887B2/en not_active Expired - Fee Related
- 2008-01-28 ZA ZA200904530A patent/ZA200904530B/xx unknown
- 2008-01-28 CA CA002673734A patent/CA2673734A1/en not_active Abandoned
- 2008-01-28 CN CN200880003310A patent/CN101616912A/zh active Pending
- 2008-01-28 CL CL200800231A patent/CL2008000231A1/es unknown
- 2008-01-28 WO PCT/JP2008/051695 patent/WO2008093853A1/ja active Application Filing
- 2008-01-28 EP EP08704375A patent/EP2116542A4/en not_active Withdrawn
-
2009
- 2009-07-28 IL IL200103A patent/IL200103A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2008093853A1 (ja) | 2010-05-20 |
CL2008000231A1 (es) | 2008-05-30 |
EP2116542A1 (en) | 2009-11-11 |
US7790887B2 (en) | 2010-09-07 |
BRPI0805837A2 (pt) | 2011-08-30 |
EP2116542A4 (en) | 2011-05-04 |
CN101616912A (zh) | 2009-12-30 |
AR065045A1 (es) | 2009-05-13 |
IL200103A0 (en) | 2010-04-15 |
KR20090104002A (ko) | 2009-10-05 |
US20080214564A1 (en) | 2008-09-04 |
NZ575828A (en) | 2011-04-29 |
CA2673734A1 (en) | 2008-08-07 |
ZA200904530B (en) | 2010-09-29 |
RU2009132476A (ru) | 2011-03-10 |
AU2008211950A1 (en) | 2008-08-07 |
WO2008093853A1 (ja) | 2008-08-07 |
MX2009008068A (es) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
CL2007002375A1 (es) | Compuestos derivados de heteroarilo, inhibidores de citocina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, inflamacion, artritis, psoriasis, diabetes, | |
CL2007002188A1 (es) | Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal. | |
CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
CL2007003244A1 (es) | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
BRPI0914599A2 (pt) | métodos para tratar ou prevenir câncer, para inibir uma pim quinase, e para fabricar um composto, composto, composição farmacêutico, e, uso de um composto | |
CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
CL2007003627A1 (es) | Compuestos derivados de 3-h-pirazolopiridinas; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades de crecimiento vascular desregulado tal como leucemia mielogena aguda, retinopatia, artritis reumatoide, psorias | |
BRPI0610359B8 (pt) | compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis | |
CL2007003609A1 (es) | Compuestos derivados de dihidropiridinas sustituidas; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; proceso para producir la composicion farmaceutica; y uso en el tratamiento de una enfermedad mejorada con la inhibicion | |
UY31765A (es) | Dihidropirazolonas sustituidas y su uso | |
CL2012000163A1 (es) | Compuestos derivados de quinazolina o pirido[2,3-d]pirimidina, inhibidores de la autofagia; composicion farmaceutica; y su uso para el tratamiento del cancer, pancreatitis, neurodegeneracion, entre otras. | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
CL2007002234A1 (es) | Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas. | |
SV2009003236A (es) | Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematologicas | |
CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
CO6290654A2 (es) | Derivados de salinosporamida como inhibidores de proteasoma | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
AR062394A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis | |
AR057099A1 (es) | Una forma cristalina, un proceso de preparacion y composicion farmaceutica | |
CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
CU20120171A7 (es) | Triazolopiridinas sustituidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |